No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AMPH240719C40000
- 0.50
- +0.25+100.00%
15min DelayClose Jul 12 15:58 ET
0.70High0.50Low
0.65Open0.25Pre Close26 Volume106 Open Interest40.00Strike Price1.78KTurnover52.56%IV4.65%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.50Extrinsic Value100Contract SizeAmericanOptions Type0.3196Delta0.1434Gamma77.40Leverage Ratio-0.0859Theta0.0018Rho24.74Eff Leverage0.0169Vega
Intraday
- 5D
- Daily
News
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
BofA Securities Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating
BofA Securities analyst Jason Gerberry maintains $Amphastar Pharmaceuticals(AMPH.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 44.4% and a total average
Bank of America Securities Reaffirms Their Hold Rating on Amphastar Pharmaceuticals (AMPH)
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only n
Insider Sale: CFO, EVP & Treasurer William Peters Sells Shares of Amphastar Pharmaceuticals ...
Amphastar Pharmaceuticals(AMPH.US) Officer Sells US$147.17K in Common Stock
$Amphastar Pharmaceuticals(AMPH.US)$ Officer PETERS WILLIAM J sold 3,596 shares of common stock on Jun 27, 2024 at an average price of $40.9258 for a total value of $147.17K.Source: Announcement What
Comments
$Amphastar Pharmaceuticals(AMPH.US$ 📣 Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
✨Bioequivalent and therapeutically equivalent to $TEVA ProAir® HFA Inhalation Aerosol
» ANDA approval
» Indication: Tx or prevention of bronchospasm 🫁
» Product launch in Q3 '24
✨Bioequivalent and therapeutically equivalent to $TEVA ProAir® HFA Inhalation Aerosol
» ANDA approval
» Indication: Tx or prevention of bronchospasm 🫁
» Product launch in Q3 '24
3
The market's growth expectations seem moderated as EPS growth outpaces average annual share price increase. The recent rise in total shareholder return could suggest business improvement over time.
The impressive EPS growth and large insider ownership make Amphastar Pharmaceuticals a potentially attractive investment. The business appears to have reached a growth inflection point.
Insider ownership is moderately high, showing company's interest for all shareholders, but the lack of insider buying and significant selling over the last year, casts some doubt on the company's outlook.
Amphastar Pharmaceuticals experienced a dip, but long-term its performance is strong due to profitability transition and faster EPS growth versus share price. However, market growth expectations are moderated. Share price momentum indicates a potential investment opportunity.
Read more